U.S. markets closed
  • S&P 500

    -51.25 (-1.34%)
  • Dow 30

    -345.95 (-1.11%)
  • Nasdaq

    -274.28 (-2.11%)
  • Russell 2000

    -60.87 (-2.76%)
  • Crude Oil

    +0.29 (+0.45%)
  • Gold

    -10.80 (-0.64%)
  • Silver

    -0.16 (-0.61%)

    -0.0011 (-0.10%)
  • 10-Yr Bond

    +0.0800 (+5.44%)

    -0.0005 (-0.03%)

    -0.1220 (-0.11%)

    -3,794.68 (-7.47%)
  • CMC Crypto 200

    -46.97 (-4.76%)
  • FTSE 100

    -24.59 (-0.37%)
  • Nikkei 225

    -421.78 (-1.46%)

BrainStorm Cell Therapeutics Presents Breakthrough Phase I/II ALS Clinical Data at the American Academy of Neurology Annual Meeting

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwire - Mar 13, 2013) - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will be presenting the initial results of its Phase I/II ALS trial at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, California, from March 16-23. BrainStorm's groundbreaking clinical trial data were selected for one of only twelve oral presentations in the Emerging Science Session on Wednesday, March 20th.

The presentation, to be made by Principal Investigator Professor Dimitrios Karussis of the Hadassah Medical Center in Jerusalem, will be the first to make public the outstanding Phase I/II clinical trial safety data and promising initial indications of clinical efficacy observed after treatment with NurOwn™, BrainStorm's stem cell therapy candidate for ALS.

"We are honored to present these important clinical data at the most prestigious world neurology meeting," commented Professor Karussis. "We are confident that the results observed so far will be indicative of the potential therapeutic benefit of NurOwn cells for treatment of ALS," he added.

The American Academy of Neurology Annual Meeting is one of the world's most important annual events for neurologists and neuroscience professionals and the largest such international meeting of its kind with more than 12,000 attendees at last year's meeting. For more information about the AAN annual meeting and for a complete list of abstracts, please refer to the conference Web site at http://www.aan.com/go/am13.

The following is the key NurOwn™-related abstract being presented at the AAN meeting:

Abstract #


Session Title


First Author




Oral + Poster Presentation

Emerging Science Session

Interim Analysis of 12 Patients w/Amyotrophic Lateral Sclerosis (ALS) Treated w/Autologous Differentiated Mesenchymal Stem Cells: Preliminary Data of a Phase I/II Clinical Trial

Dimitrios Karussis, MD, PhD

Wednesday March 20


About NurOwn™
NurOwn is an autologous, adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells (MSC) into specialized, neuron-supporting cells. These neuron-supporting cells (known as "MSC-NTF" cells) secrete neurotrophic, or nerve-growth, factors for PROTECTION of existing motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT of nerve-muscle interaction. The ability to differentiate mesenchymal stem cells into MSC-NTF cells, and confirmation of their activity and potency before transplantation, makes NurOwn a first-of-its-kind approach for treating neurodegenerative diseases. More information about NurOwn™ can be found at http://brainstorm-cell.com/index.php/science-a-technology/-nurown.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com.

Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.